POST Online Media Lite Edition



 

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Christian Fernsby |
Pharming Group announces that the first patient has been enrolled in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS).

Article continues below




There is currently no approved treatment for this complex and progressive disease caused by genetic variants.

At sites in the United States, Europe, and Japan, the single-arm, open-label, multinational clinical trial will evaluate the safety, tolerability, and efficacy of leniolisib in approximately 15 children aged 4 to 11 years who have a confirmed APDS diagnosis.

The study's primary efficacy endpoints are a reduction in index lymph node size and an increased proportion of naïve B cells out of total B cells from baseline at 12 weeks.

Secondary endpoints include an assessment of the ability of leniolisib to modify health-related quality of life based on measures of physical, social, emotional, and school functioning using a validated patient questionnaire.

Pharming plans to initiate a similar clinical trial in the third quarter of 2023 that will include children aged 1 to 6 years, with APDS, to evaluate a new pediatric formulation of leniolisib.

Eligible patients enrolled in either of the pediatric trials will continue to receive leniolisib for a year after the initial 12-week treatment period through an open-label extension trial.

Manish Butte, MD, PhD, E. Richard Stiehm Endowed Chair, Professor with tenure in the Department of Pediatrics, and Division Chief of Immunology, Allergy, and Rheumatology at UCLA, commented:

"In treating APDS, the current standard of care is to use an array of supportive therapies. While these therapies can treat some of the manifestations of APDS, they do not target the underlying cause of the disease. Pharming's studies of leniolisib in children with APDS are important for evaluating the possibility of minimizing symptoms earlier in the disease progression."

Pharming's program for the clinical development of leniolisib in pediatric APDS is supported by positive data from a Phase II/III clinical trial that investigated the drug as a treatment for patients with the disease aged 12 years and older.

Recently detailed in Blood1, the international medical journal of the American Society of Hematology, the trial met both its co-primary endpoints, with patients who took leniolisib versus placebo achieving significant reductions in lymphoproliferation as measured by index lymph node size and increases in immunophenotype corrections as measured by the percentage of naïve B cells in peripheral blood.

During the first half of 2022, positive opinions were received from the European Medicines Agency (EMA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) on the Pediatric Investigation Plan (PIP) for leniolisib as a treatment for APDS in children. The PIP(s) included the plans for both pediatric clinical trials.

Based on the Phase II/III trial results and long-term open-label extension data, the U.S. Food and Drug Administration (FDA) is conducting a priority review of Pharming's New Drug Application for leniolisib as a treatment for adolescents and adults with APDS and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29, 2023.

In addition, Pharming's Marketing Authorisation Application (MAA) for leniolisib in the same patient population is under evaluation by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

Pharming expects that the CHMP will issue its opinion on the leniolisib MAA in 2H 2023.

APDS is a rare primary immunodeficiency that affects approximately 1 to 2 people per million. APDS is caused by variants in either of two genes, PIK3CD or PIK3R1, that regulate maturation of white blood cells.

Variants of these genes lead to hyperactivity of the PI3Kδ (phosphoinositide 3-kinase delta) pathway.2,3 Balanced signaling in the PI3Kδ pathway is essential for physiological immune function. When this pathway is hyperactive, immune cells fail to mature and function properly, leading to immunodeficiency and dysregulation.

APDS is characterized by severe, recurrent sinopulmonary infections, lymphoproliferation, autoimmunity, and enteropathy. Because these symptoms can be associated with a variety of conditions, including other primary immunodeficiencies, people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.

As APDS is a progressive disease, this delay may lead to an accumulation of damage over time, including permanent lung damage and lymphoma.5-8 A definitive diagnosis can be made through genetic testing.

Leniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K. PI3Kδ is expressed predominately in hematopoietic cells and is essential to normal immune system function through conversion of phosphatidylinositol-4-5-trisphosphate (PIP2) to phosphatidylinositol-3-4-5-trisphosphate (PIP3).

Leniolisib inhibits the production of PIP3 and PIP3 serves as an important cellular messenger activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation, differentiation, cytokine production, cell survival, angiogenesis, and metabolism.

Unlike PI3Kα and PI3Kβ, which are ubiquitously expressed, PI3Kẟ and PI3Kγ are expressed primarily in cells of hematopoietic origin.

The central role of PI3Kẟ in regulating numerous cellular functions of the adaptive immune system (B-cells and, to a lesser extent, T cells) as well as the innate immune system (neutrophils, mast cells, and macrophages) strongly indicates that PI3Kẟ is a valid and potentially effective therapeutic target for immune diseases such as APDS.

To date, leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study in patients with APDS.


What to read next

Pharming says EMA validates its MAA under accelerated assessment for leniolisib
Pharming announces FDA acceptance for priority review of its new drug application for leniolisib
Pharming submits marketing authorisation application to EMA for Leniolisib

U.S.: Powerful storm to impact western part; fire weather concerns for areas of Plains

 
A significant winter storm will impact much of the West heading into the weekend, including dangerous, blizzard conditions for the Sierra Nevada.
 
 

Latest

Oil rig count up to 629
MF Meats recalls meat contaminated with oil not for food
€1.9 million from European Globalisation Adjustment Fund to support 390 dismissed workers in Denmark
€3 million from European Globalisation Adjustment Fund to support 835 dismissed steel workers in Germany

NEWS

Europol supports EPPO investigation into EUR 195 million VAT fraud scheme

Zambia declares state of disaster due to drought
No agreement reached between Polish PM and protesting farmers
1 dead, 2 missing as fishing boat capsizes off South Korea's southern island
Residents near collapsed mine in Venezuela continue to be evacuated
Croatia: 2 arrested on suspicion of agricultural subsidy fraud and document forgery
 

BUSINESS

One in three Swiss companies pays bribes abroad

Indonesia launches ammonium nitrate plant to boost food self-sufficiency
Work to deliver Midlands Rail Hub set to begin with £123 million
British Columbia’s minimum wage increases to $17.40 an hour on June 1
Madrid Metro Line 3 extension now 65% complete
Saudi Arabia launches new clean Euro 5 fuels
 

Trending Now

Italy regulator fines Enel unit 79 million euros for telemarketing abuses

Three partners unite for landmark hybrid wind-solar farm offshore Italy

New Zealand develops salmon farming in open sea

JoS. A. Bank appoints Byron Bergren to its board


POLITICS

Morocco aims to manufacture first plane by 2030

$30 million in initial SEEDS grants to accelerate development of industrial sites across Alabama
$7.5 million state investment supports Illinois' growing EV industry and workforce
Russia to ban gasoline exports for 6 months starting March 1
Qatar announces new LNG expansion project
Local leaders to receive £4.7 billion to transform transport across North and Midlands
 

Today We Recommend

Morocco aims to manufacture first plane by 2030


Highlights 

Infineon Technologies announces over 100 new jobs in Ireland

Macy's to shut 150 stores in growth, revitalization plan

Kyowa Kirin to bring more than 100 new jobs to Sanford, North Carolina


COMPANIES

Three partners unite for landmark hybrid wind-solar farm offshore Italy

Ethiopian inaugurates first of its kind e-commerce logistics facility at Bole International Airport
Exxon files lawsuit against climate activist investors Arjuna Capital and Follow This
Germany's KWS launches phase two of seed plant in Ukraine
Safran Aircraft Engines establishes new foundry in Rennes, Brittany for turbine blade manufacturing
Poland's Cargounit invests in Siemens locomotives for European rail modernization
 

CAREERS

Oxehealth appoints Todd Haedrich as CEO

Alan Berger joins Multi-Wing global board as non-executive director
BioMar appoints new VP for Asia
APO Group appoints Laila Bastati as chief commercial officer
TerraPay appoints Ruben Salazar Genovez as president
Personetics names Udi Ziv as new CEO
 

ECONOMY

South Korea's export grows for 5th straight month in February

Finland's economy contracted by 1.0 pct in 2023
Austria's GDP shrinks 0.8 pct in 2023
Canada's economic growth slows in 2023
U.S. Q4 GDP slightly revised down to 3.2 pct
More 15 and 16 year olds in Netharlands in paid work
 

EARNINGS

Dell Technologies Q4 revenue $22.3 billion

Hormel Foods Q1 sales $3.0 billion
Fortaco Q4 sales EUR 101.9 million
Statkraft delivered its second highest result
Dar Global revenues $360.6 million
Best Buy Q4 profit $460 million
 

OP-ED

Micromanaging is the worst enemy of efficiency and teamwork

Niger set to monetize massive gas reserves through Saharan natural gas pipeline
Putting the brakes on EV folly that choked the market
Oil discovery in Kavango Basin may mean huge benefits for Namibians
Cape Town and Dubai battle over Africa's energy future
Is America going to lose its superpower status?
 

AGRIFISH

New Zealand develops salmon farming in open sea

State Veterinarian confirms rabies in Middle Tennessee horse
Census of agriculture reveals increase in number of farms in New Jersey
Qatar imposes import restrictions on Jordanian leafy vegetables
Population growth of “bee hunting fly” detected in Buenos Aires
Philippines formally accepts Agreement on Fisheries Subsidies
 

LEADERSHIP

Generating 'buzz' about new products can influence their success

Hiring 'problem directors' can knock up to 64% off firm's value
Problematic 'zombie leadership' lives on in many cases
Younger workers have significantly lower productivity than older
Employees who experienced burnout valued jobs with training opportunities less
Moderate performance goals let workers adapt to turbulent marketplaces, research suggests
 

CRIME

Sandoz pays $265 million for settlement in U.S.

Italy regulator fines Enel unit 79 million euros for telemarketing abuses
Family Dollar fined $42 mln for storing food, drugs in rodent infested warehouse
Former Vitol oil trader convicted of corruption
Three NRA leaders found liable for graft
Linde unit to pay $25.5 mln over claims it defrauded U.S. healthcare programs
 

Magazine

TRAVEL

Experience the thrill of walking across the breathtaking Ruyi Bridge

Share your story in Denver StorySlam in just five minutes
The Garden of Ninfa, Rome's dreamy romantic getaway
Visitors to be welcomed back on Farne Islands
Hotel Taschenbergpalais Kempinski Dresden opens
306 Room Tempo by Hilton Nashville Downtown hotel opens
 

SEA, LAND, AIR

Pagani Huayra R Evo, 900 hp from 770 Nm

Embraer Phenom 300E, true force to be reckoned with
Sikorsky S-76D helicopter, for perfect business travel above roads
Porsche Taycan, improved in almost everything
New Ford Explorer is all about exploring
Chevrolet 2025 Equinox is new and refreshed
 

DESIGN

Luxury duvet looks good, fells good and keeps you healthy

Vacheron Constantin, watches for life and more
Schüller kitchens, where functionality marries design
Marc Kaufman Furs, from glory days of Wild West to fashion empire
Kelaghayi scarf, powerful women's fashion symbol from Azerbaijan
Tiffany reimagined their necklace collections in bold style
 

GADGETS

Casette tapes are making a big comeback, and so are portable players

Neumann TLM 103, standard microphone for both voice and music
Epikore Epikore, luxurious loudspeakers you should have
Retro radios with soul for your car
Balanced Audio Technology power amplifier REX 500, 500 watts of solid state
Marantz TT-15S1 turntable, excellent materials and sound
 

HEALTH

Nutraceutical recalls thousands of bottles of mouthwash due to poisoning risk

New microbiome insights could help boost immunotherapy for range of rare cancers
Vaping can increase susceptibility to infection by COVID-19
AstraZeneca's Voydeya treatment recommended for EU approval
GSK gonorrhoea treatment achieves efficacy endpoint in latest trial
Secret, undeclared pesticide ingredients may pose risk to people, pollinators and environment
 

MEANTIME

Scientists discover radiation from massive stars shapes planetary systems

Avian influenza virus adapting to spread to marine mammals
China's first 'ground space station' passes acceptance review
India unveils astronaut-designates for its first human spaceflight
Australian research discovers 8 new Pacific bee species
Significant glacial retreat in West Antarctica began in 1940s